IL23抗体;IL23 Antibody—艾普蒂

+ +

•  

   

     Result: P15114 can detect human IL23A by Western blotting.    

  
  

Interleukin-23 (IL-23) is a pro-inflammatory cytokine belonging to the IL-12 family, primarily produced by activated dendritic cells and macrophages. It plays a pivotal role in chronic inflammation and autoimmune diseases by promoting the differentiation and maintenance of T helper 17 (Th17) cells, which secrete inflammatory cytokines like IL-17 and IL-22. Dysregulated IL-23 signaling is implicated in conditions such as psoriasis, inflammatory bowel disease (IBD), and psoriatic arthritis.

IL-23 antibodies are biologic therapies designed to block this pathway. These monoclonal antibodies target either the IL-23-specific p19 subunit or the shared p40 subunit of IL-23 and IL-12. Early agents like ustekinumab (anti-p40) showed efficacy but lacked specificity. Newer antibodies, such as risankizumab, guselkumab, and tildrakizumab, selectively inhibit IL-23 by binding to p19. minimizing off-target effects. By neutralizing IL-23. these antibodies disrupt Th17-mediated inflammation, reducing disease activity.

Approved for moderate-to-severe plaque psoriasis and undergoing trials for IBD, IL-23 inhibitors offer improved safety profiles compared to broader immunosuppressants. Their development reflects a shift toward targeted immunomodulation, emphasizing precision in treating autoimmune disorders. Research continues to explore their potential in other IL-23-driven conditions, solidifying their role as transformative therapies in autoimmune care.